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Objectives. We sought to investigate the nature of terminal
events and potential contributory clinical and nonclinical (e.g.,
device-related) factors associated with sudden death (SD) in
recipients of an implantable cardioverter-defibrillator (ICD).
Background. The ICD is very effective in terminating ventricu-
lar tachycardia (VT) or ventricular fibrillation (VF), but protec-
tion against SD is not absolute. Little is known about the nature
and potential causes of SD in patients with ICDs.
Methods. We analyzed 25 cases of out-of-hospital SD among
patients enrolled in the clinical investigation of the Cadence
Tiered-Therapy Defibrillator System.
Results. All patients (24 men and 1 woman, mean age 62 6 10
years) received epicardial lead systems. The majority (92%) had
coronary artery disease and a previous myocardial infarction (MI),
with a mean left ventricular ejection fraction 0.25 6 0.07. At device
implantation, the mean defibrillation threshold was 13 6 5 J. Sud-
den death occurred 13 6 11 months later. Twenty patients (80%) had
received appropriate ICD therapies before death, and 18 (72%) were
receiving >21 antiarrhythmic drugs at the time of death. Sudden
death was tachyarrhythmia-associated in 16 patients (64%), non-
tachyarrhythmia-associated in 7 (28%) and indeterminate in 2 (8%).
In the 16 patients with tachyarrhythmia-associated SD, the overall
first therapy success rate in tachycardia and fibrillation zones was
60% and 67%, respectively. However, despite protracted therapies
(>22 shocks) in 7 (66%) of 12 patients who received fibrillation
therapies, the final tachyarrhythmic episode was ultimately termi-
nated by the ICD in 15 (94%) of the 16 patients, whereas 1 patient
died after multiple (initially successful) internal and external shocks
for intractable VT/VF during exercise. In 10 patients (40%) one or
more, primarily clinical, factors potentially contributory to SD were
identified: heart failure (n 5 8), angina (n 5 2), hypokalemia (n 5
1), adverse antiarrhythmic drug treatment (n 5 1) and acute MI
(n 5 1). An additional 10 patients (40%) had experienced an increase
in frequency of ICD shocks within 3 months of SD. Appropriate
battery voltages and normal circuitry function were found in all
devices interrogated and analyzed after death.
Conclusions. In this select group of patients receiving a third-
generation ICD, SD was associated with VT or VF events in nearly
two-thirds of patients, and death occurred despite ultimately
successful, although often protracted, device therapies. These
observations, along with evidence of recent worsening clinical
status, suggest acute cardiac mechanical dysfunction as a fre-
quent terminal factor. In recipients with ICDs, SD directly
attributable to device failure seems to be rare.
(J Am Coll Cardiol 1999;33:24–32)
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The efficacy of implantable cardioverter-defibrillator (ICD)
therapy for treatment of ventricular tachyarrhythmias has been
well documented (1). However, the protection afforded by the
ICD against sudden arrhythmic death is not absolute. Insight
into the nature of terminal events associated with sudden
death (SD) in ICD recipients has been limited by the relatively
low incidence of this outcome as well as the inability, until
recently, to document the arrhythmias occurring just before
death. A few reports have described terminal events in patients
with first-generation ICDs who died suddenly (2–5). In the
largest of these studies (5), involving 51 cases of SD, nearly
two-thirds occurred in association with known or presumed
tachyarrhythmia, with one or more contributory factors, such
as battery depletion or device deactivation, identified in more
than half of the patients. The extent to which these observa-
tions in patients with first-generation ICD also apply to the
occurrence of SD in patients with newer devices is not known.
The event storage capability of the more recent generation
of ICDs, including intracardiac electrograms (6), offers the
possibility of better characterization of terminal arrhythmias
associated with SD (7). At the same time, various technologic
features of the newer devices, such as biphasic shock (which
provides for lower defibrillation energy [8]) and antibradycar-
dia pacing, might have a positive impact on patient outcome,
whereas enhanced programmability, with the potential for
suboptimal device responses (9), might have adverse conse-
quences.
The objectives of this study were twofold: first, to determine
the arrhythmic events associated with SD in recipients of a
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third-generation ICD and, second, to identify clinical and
possible device-related factors that might have contributed to
the patients’ death, and whether or not such factors, if any,
might be potentially preventable.
Methods
Study group. Between July 1989 and April 1993, a total of
1,846 patients received, as part of a clinical investigation, the
Cadence (V-100) Tiered-Therapy Defibrillator System (Ven-
tritex, Sunnyvale, California) for treatment of life-threatening
ventricular tachycardia (VT) and ventricular fibrillation (VF).
After a mean follow-up of 13 6 11 months (range 0 to 45)
outcome data were available in 1,649 patients: 37 (2%) had an
SD, 168 (10%) had a non-SD and the remaining 1,447 (88%)
were alive. Of these 37 patients who died suddenly, 7 were
excluded at the outset of our analysis: 3 because of physician
nonparticipation in the study; 3 whose ICDs had been inten-
tionally deactivated beforehand; and 1 who died suddenly
before hospital discharge, after receiving defibrillation leads
only. Five (17%) of the remaining 30 patients died in the
hospital, during the first week after the operation; they were all
monitored and observed to receive multiple ICD shocks for
VT or VF, with eventual asystole/electromechanical dissocia-
tion (EMD). Each of the five patients had been hemodynam-
ically stable up to the onset of VT/VF, but two had evidence of
acute myocardial infarction (MI) on postmortem examination.
As postoperative deaths in ICD recipients have been attrib-
uted to arrhythmia “exacerbation” after implantation of
epicardial-lead ICDs (10,11), and may not be representative of
SD events in an outpatient setting, we restricted the study
group to the remaining 25 patients who had an out-of-hospital
SD with active ICDs.
Device system and implantation. The Cadence ICD is a
multiprogrammable device capable of backup bradycardia
pacing and “noncommitted” antitachycardia pacing, cardiover-
sion and defibrillation with biphasic shocks (12). Detailed
information on the detected tachyarrhythmic events, including
each delivered therapy and its duration and outcome, is
available for each of the most recent 11 episodes. The device
stores intracardiac electrograms corresponding to the most
recent (#3) tachyarrhythmic events, along with the time and
date of the events. The device’s extended high rate (EHR)
detection feature incorporates a “timer” that allows antitachy-
cardia therapies to be attempted for only a programmable
length of time (10 to 120 s); if the timer expires, the device
proceeds to the more aggressive fibrillation zone therapies
(12).
Written informed consent for implantation of this device
(investigational at the time) was obtained from all patients
after approval by the Institutional Review Boards of each of
the participating centers (see Appendix). All 25 patients
received epicardial lead systems consisting of two defibrillating
patches and epicardial (n 5 14) or endocardial (n 5 11)
rate-sensing leads. Four patients had concomitant myocardial
revascularization.
Patient follow-up and data collection. A complete evalua-
tion of device function, including VT and VF therapy, was
performed before and 6 weeks after hospital discharge, and per
the discretion of the individual electrophysiologist depending
on clinical circumstances (e.g., addition or change in antiar-
rhythmic drug therapy). Thereafter, patients were seen at a
minimum of once every 3 months, or sooner in cases of device
discharges. At each visit, the device was interrogated and all
diagnostic-therapy data, including intracardiac electrograms,
stored since the previous visit were recorded. Retrieved data
obtained from postmortem device evaluation were analyzed
with emphasis on the number of detected and treated
tachyarrhythmic episodes and the outcome of each therapy.
These and any other pertinent data were reviewed after being
submitted to Ventritex from each of the participating centers.
Death classification. Sudden death was defined as death
occurring within 1 h of symptoms or during sleep or unwit-
nessed in a previously medically stable patient (13), and was
further classified on the basis of the presence or absence of
tachyarrhythmias at the time of death: 1) Tachyarrhythmia-
associated: In witnessed patients, documented ICD shocks or
VT/VF during resuscitation, plus new tachyarrhythmic events
(from ICD data log) at the time of death; or, in unwitnessed
patients, evidence of delivered ICD therapy on the day of
death. Stored intracardiac electrograms of specific tachyar-
rhythmias were classified according to published criteria (6).
Tachyarrhythmia cycle length was determined on the basis of
an average of 10 beats immediately preceding a delivered or
aborted therapy. 2) Non-tachyarrhythmia-associated: Death in
the absence of stored, new tachyarrhythmic events in unwit-
nessed patients, or documented asystole or EMD not imme-
diately preceded by antitachyarrhythmic ICD therapy in wit-
nessed, monitored patients. 3) Indeterminate: Insufficient
information regarding either postmortem device data or wit-
nessed shocks or documented tachyarrhythmia at the time of
death.
Statistical analysis. Numeric values are expressed as the
mean value 6 SD or percentage. Comparisons were made
using the Student t test, with p values ,0.05 considered
significant.
Abbreviations and Acronyms
CHF 5 congestive heart failure
DFT 5 defibrillation threshold
EHR 5 extended high rate
EMD 5 electromechanical dissociation
ICD 5 implantable cardioverter-defibrillator
LVEF 5 left ventricular ejection fraction
MI 5 myocardial infarction
SD 5 sudden death
VF 5 ventricular fibrillation
VT 5 ventricular tachycardia
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Results
Baseline clinical and implantation data. Baseline charac-
teristics of the 25 study patients are summarized in Table 1.
There were 24 men and 1 woman with a mean age of 62 6 10
years (range 41 to 79), and 92% had coronary artery disease
with a previous acute MI and a mean left ventricular ejection
fraction (LVEF) of 0.25 6 0.07 (range 0.12 to 0.40); five
patients had previous coronary artery bypass graft surgery.
Seventeen patients presented with sustained VT, five with VF
and three with syncope and inducible sustained VT. A mean of
2.6 6 1.4 (range 0 to 5) antiarrhythmic drugs were tried before
ICD therapy. At device implantation, the mean defibrillation
threshold (DFT) was 460 6 126 V (13 6 5 J), and the R wave
amplitude was 12 6 5 mV (range 5 to 22).
Follow-up events. Sudden death occurred 13 6 11 months
(range 0.2 to 45) after device implantation. All but one patient
(no. 23), who had spontaneous, appropriate device therapies in
the first week after implantation had $1 postimplantation
assessment of device function showing appropriate detection
and termination of induced VF and, when applicable, VT.
Twenty-one patients (84%) had a history of $1 appropriate
device therapy for either VT or VF, or both. Eighteen patients
(72%) were receiving $1 antiarrhythmic drug at the time of
death, including amiodarone alone or combined with another
agent in five patients.
Characterization of terminal events. Death was witnessed
in 18 (72%) of the 25 patients. In 13 of the 18 witnessed
patients with available relevant data, 8 (62%) had no premon-
itory symptoms before collapse, and the remaining 5 (38%)
complained of chest pain or respiratory distress within minutes
of, or immediately preceding, collapse. Eight (44%) of the 18
witnessed patients were reported to have received ICD shocks
at the time of collapse; 4 (22%) were observed specifically not
to have received shocks; and in the remaining 6 (34%),
information on shock delivery was available. In 20 patients for
whom EMS was summoned soon after collapse, the following
rhythms were reported (Table 1): VF in 5, VT in 3 and
paced/EMD in the remaining 12. All 20 patients received
advanced resuscitative measures with an unsuccessful out-
come. Six of the seven unwitnessed patients had been seen in
stable condition within 1 to 24 h before death.
Postmortem device analysis. Device interrogation was
completed after death in 22 (88%) of 25 patients: 15 (68%)
had new tachyarrhythmic events stored at the time (witnessed
patients) or on the day of death (unwitnessed patients), and
the remaining 7 (32%) had no new stored tachyarrhythmic
events. Retrieved electrograms corresponding to the most
recent #3 stored tachyarrhythmic events showed VT or VF in
14 patients and “make-break” potentials resulting from cut
rate-sensing leads during autopsy in one patient (no. 25). The
Table 1. Summary of Clinical, Implantation, Follow-Up and Postmortem Device Data on the 25 Study Patients
Pt.
No
Age/
Gender OHD EF
NYHA
Functional
Class
Clinical
Presentation
Implant Data
No. of
Premortem
VF Tests*
History of
Appropriate†
ICD Rx
Change in
premortem (#3 mos)
Clinical Status
AA
Drug at
Time of
Death
DFT
(J/V)
R Wave
(mV)
1 79/M CAD 0.3 II VT 8/350 7 2 Yes CHF, 1shocks PA, AM
2 61/M IDCM — II VT 8/350 5 1 Yes 1Shocks Toc, Enc
3 51/M CAD 0.3 II Syncope 11/400 6 2 Yes 1Shocks Am
4 61/M CAD 0.2 II VT 10/550 16 2 Yes 1Shocks Ethm
5 67/M CAD — II VT 16/490 13 2 No CHF None
6 52/M CAD 0.3 II VF 16/470 13 3 Yes No Am
7 41/M CAD 0.3 III VT 8/550 20 1 No — None
8 74/M CAD 0.3 II VF 17/600 19 2 No No None
9 53/M CAD 0.2 II VT 11/350 7 2 Yes 1Shocks Mx
10 45/M CAD 0.2 II VF 10/450 6 2 No CHF, angina None
11 75/F CAD 0.4 I VT 7/300 14 2 Yes No None
12 68/M CAD 0.1 III VT 20/550 5 2 Yes CHF Am
13 60/M CAD 0.2 II VF 12/300 10 2 Yes CHF, 1shocks Q, Mx
14 67/M CAD 0.3 II Syncope 11/400 13 2 Yes CHF Mx
15 74/M IDCM 0.3 I VT 20/550 20 1 Yes No PA
16 66/M CAD 0.3 II VT —/300 13 2 Yes 1Shocks Q
17 59/M CAD 0.2 II VT 16/580 16 2 Yes Angina Toc, Pf
18 70/M CAD — II VT 24/600 10 1 Yes No Q, Mx
19 60/M CAD 0.37 I VT 11/390 21 2 Yes CHF Sot
20 51/M CAD 0.23 II VT —/650 11 2 Yes CHF, 1shocks PA, Mx
21 67/M CAD 0.20 III Syncope 13/450 10 1 No No Am
22 66/M CAD 0.18 II VT 15/470 22 2 Yes No —
23 69/M CAD 0.31 II VT 10/453 6 0 Yes 1Shocks —
24 56/M CAD 0.30 II VF —/750 11 2 Yes 1Shocks Sot
25 48/M CAD — II VT —/200 12 1 No No Pf
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cycle lengths of stored VT and VF events were 260 to 370 ms
and #250 ms, respectively. In each of the 14 patients these
final #3 VT or VF events were stored within seconds to
minutes apart, consistent with closely timed recurrent VT/VF.
Appropriate battery voltages (.5.1 V) were noted in all 22
patients whose devices were interrogated after death, and
shock impedance was in the normal range (28 to 60 ohms) in
the 8 patients with available data (Table 1). Analysis per-
formed at Ventritex on the 21 returned generators showed no
evidence of circuitry malfunction.
Tachyarrhythmia-versus nontachyarrhythmia-associated
SD. Based on documentation of VT/VF during attempted
resuscitation, witnessed ICD shocks (presumptive VT/VF) or
stored ICD data, or a combination, SD was considered
tachyarrhythmia-associated in 16 patients, nontachyarrhythmia-
associated in 7 and indeterminate in 2 (Fig. 1). Of the two
indeterminate cases (both witnessed), information on ICD
shocks, EMS documented rhythm or device interrogation was
not available in one patient (no. 24); the other patient (no. 25)
most likely represented a nontachyarrhythmia-associated
death because the patient had received no shocks at the time of
collapse.
As shown in Table 2, relying on various criteria, the
proportion of known or presumed tachyarrhythmic events in
witnessed patients ranged from 67% (based on reported ICD
shocks) to 79% (based on stored electrograms showing VT or
VF). Three (43%) of the seven unwitnessed patients were
presumed to have tachyarrhythmia based on evidence of new
tachyarrhythmic events stored on the day of death.
Comparison of clinical characteristics of patients with
tachyarrhythmia- versus nontachyarrhythmia-associated SD. Al-
though the number of patients in either of these categories is
small, the two groups were similar with respect to mean age,
prevalence of coronary artery disease, baseline LVEF, New
York Heart Association functional class, preterminal new or
worsening congestive heart failure (CHF), use of antiarrhyth-
Table 1. Continued
Follow-up
(mos)
Terminal Events Postmortem ICD Analysis (mos)
Location at
Onset Witnessed
Reported
Shocks
First
Documented
Rhythm‡
New Stored
Tachyarrhythmic
Events§
Battery
(V)
Shock
Impedance\
Detected
Malfunction¶
18 OOH Yes Yes VF Yes 5.9 47 No
0.3 OOH Yes Yes VT Yes .6.0 34 No
17 OOH Yes Yes VF Yes 5.8 47 No
7 OOH Yes Yes Paced Yes .6.0 — —
15 OOH Yes Yes Paced Yes .6.0 — No
32 OOH Yes Yes VF Yes 5.1 53 No
3 OOH Yes Yes VF — — — —
6 OOH Yes Yes VF — — — —
14 OOH Yes — VT Yes .6.0 60 No
26 OOH Yes — VT Yes .6.0 — No
19 OOH Yes — Paced Yes .6.0 40 No
45 OOH Yes — Paced Yes 5.3 — No
36 OOH Yes — Paced Yes 5.6 — No
5 OOH No — Paced Yes .6.0 43 No
0.03 OOH No — Paced Yes .6.0 28 No
23 OOH No — — Yes .6.0 — No
25 OOH Yes No Paced No .6.0 — No
2 OOH Yes No Paced No .6.0 — No
39 OOH Yes No Paced No 5.3 — No
3 OOH No — Paced No .6.0 — No
0.2 OOH No — — No .6.0 — No
23 OOH No — — No 6.0 — No
3 OOH No — — No .6.0 — No
16 OOH Yes — — — — — —
0.5 OOH Yes No Paced Yes .6.0 — No
*Includes prehospital discharge tests; patient no. 23 had no testing but received several spontaneous, appropriate therapies before death. †Therapy for ventricular
tachyarrhythmias, before the terminal event, documented by either telemetry/Holter monitor or stored intracardiac electrograms. ‡Obtained by the emergency medical
service or from hospital telemetry; all patients in paced rhythm were in electromechanical dissociation. §From time or day of death; date and time of final #3
tachyarrhythmia episodes obtained from retrieved, stored intracardiac electrograms. \Provided only if the last high voltage therapy occurred in the last (most recent)
tachyarrhythmia episode listed in the Therapy Sequencing data log. ¶Based on analysis performed at Ventritex on returned devices. AA 5 antiarrhythmic; Am 5
amiodarone; CAD 5 coronary artery disease; CHF 5 congestive heart failure; DFT 5 defibrillation threshold; EF 5 ejection fraction; Enc 5 encainide; Ethm 5
ethmozine; ICD 5 implantable cardioverter-defibrillator; IDCM 5 idiopathic dilated cardiomyopathy; J 5 joule; Mx 5 mexiletine; NYHA 5 New York Heart
Association; OHD 5 organic heart disease; OOH 5 out of hospital; PA 5 procainamide; Pf 5 propafenone; Q 5 quinidine; Rx 5 therapy; Sot 5 sotalol; Toc 5
tocainide; VF 5 ventricular fibrillation; VT 5 ventricular tachycardia; V 5 volts.
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mic drugs at the time of death and prevalence of symptoms just
before witnessed collapse; and a similar proportion of patients
(75%) in each group had used their devices against tachyar-
rhythmias before the terminal event. Moreover, both groups
had similarly programmed bradycardia pacing rate ($40 beats/
min), including one patient (no. 19) who had a separate VVI
pacemaker with a programmed lower rate of 70 beats/min; and
a similar proportion of witnessed patients in each group had no
premonitory symptoms before collapse.
Results of antitachyarrhythmia therapy in cases of
tachyarrhythmia-associated SD. Table 3 summarizes tachyar-
rhythmia detections and ICD therapies in patients with
tachyarrhythmia-associated SD, excluding those patients (nos.
7 and 8) who did not have postmortem ICD interrogation.
Programmed ICD configuration at time of death. In 9 (64%)
of 14 patients the devices were programmed in a tiered,
two-zone mode. In 8 (57%) of the 14 patients the programmed
voltage for the first defibrillation shock exceeded the implant
DFT by 100 to 280 V (i.e., .10 J), but in 6 patients this voltage
margin ranged only from 250 to 50 V. In cases where the
device was programmed in a two-zone configuration, the EHR
detection time was set between 10 and 90 s, and the detection
interval was typically programmed equal to the tachycardia
zone detection interval. However, in one patient (no. 11) the
EHR detection interval was unconventionally set equal to the
fibrillation zone detection interval (#330 ms) and, in addition,
only a single therapy was specified for the tachycardia zone
(i.e., the second through fourth tachycardia zone therapies
were programmed “OFF” without a high-rate “timer” limit).
Tachyarrhythmia detections and therapy data. Between the
time of last ICD interrogation and death (42 6 29 days [range
5 to 90]), an average of 18 (range 1 to 108) and 11 (range 0 to
80) VT and VF detections, respectively, were recorded, for
which an average of 23 (range 0 to 94) shocks were delivered
and 3.7 (range 0 to 11) were aborted (for presumed nonsus-
tained tachyarrhythmic episodes). Three patients (nos. 5, 12
and 14) received #2 shocks and one patient (no. 13) received
only antitachycardia pacing for seven episodes of tachyarrhyth-
mias.
Success rate of first therapies. Although most tachyarrhyth-
mia therapies were ultimately successful (see later discussion),
the first and, in some cases, subsequent therapies did not
terminate the tachyarrhythmias. Specifically, of 11 patients
who received shocks for tachyarrhythmias in the fibrillation
zone, the first therapy was unsuccessful on $1 occasion in 7
(64%), yielding an overall first-therapy success rate of only
67% based on the total number of VF episodes (i.e., 62
successes in 92 episodes). Among the seven patients who
received at least two consecutive fibrillation zone shocks on
one or more occasion, four (nos. 2, 6, 9 and 11) (Table 3)
required all six shocks (the maximal number delivered by the
device for any given tachyarrhythmia episode). For tachyar-
rhythmias in the tachycardia zone, in 6 (75%) of 8 patients
initial antitachycardia pacing therapy failed on $1 occasion,
representing an overall success rate of 60% (i.e., 30 of 50
episodes).
Outcome of final therapy. Despite delivery of consecutive
$2 fibrillation zone therapies in seven patients, all VT/VF
episodes were ultimately terminated by the device in 11 (85%)
of 13 patients; one patient (no. 10) had only nonsustained
(aborted) events. One patient (no. 4) with an ethmozine-
induced rise in DFT died during a treadmill test after multiple,
initially effective, ICD and, after device inactivation, external
shocks for intractable VT/VF. In an additional witnessed
patient (no. 5) who received two appropriate ICD shocks (Fig.
2, A and B), the final intracardiac electrogram (Fig. 2C)
registered '38 min after the patient’s collapse, showed inap-
propriate redetection of “sinus rhythm” in the presence of
ongoing polymorphic VT. The two patients (nos. 7 and 8)
without postmortem ICD data were both witnessed at the time
of collapse and reported by emergency medical staff and
emergency room personnel to have received successful ICD
shocks for recurrent VF, but eventually developed EMD.
Potential contributing factors to SD. During the 3 months
before death, 10 (40%) of the 25 patients had one or more
Figure 1. Pie chart illustrating the proportions of types of arrhythmic
events associated with SD in ICD recipients who died out of the
hospital.
Table 2. Evidence of Terminal Tachyarrhythmic Events in the 25
Patients Who Had Out-of-Hospital Sudden Death
Witnessed
(n 5 18)
Unwitnessed
(n 5 7)
Patients With
Postmortem
ICD Data
(n 5 21)*
Reported shocks 8/12 (67%)† NA 8 (38%)
Documented VT or VF 8/17 (47%)‡ 0 8 (38%)
Shocks or VT/VF 10 (56%) NA 10 (48%)
Stored tachyarrhythmic EGMs
from day of death§
11/14 (79%) 3 (43%) 14 (67%)
*Excludes three patients (nos. 7, 8 and 24) lacking postmortem interrogation
and one patient (no. 25) whose stored intracardiac electrograms were filled with
postmortem “make-break” potentials from cut rate-sensing leads. †Information
regarding shock delivery (presence or absence) was available in only 12 of the 18
witnessed patients. ‡Obtained from 17 patients monitored by emergency medical
service. §Denominator values refer to number of patients in a given category with
available implantable cardioverter-defibrillator data. Data expressed as number
(%) of patints. EGMs 5 electrograms; NA 5 not applicable; other abbreviations
as in Table 1.
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notable change in clinical status (Table 1): new or worsening
CHF (n 5 8) and angina (n 5 2) and adverse antiarrhythmic
drug effect (n 5 1); and an additional 10 patients (40%) had an
increase in the frequency (.3 episodes) of ICD shocks. At the
time of death, hypokalemia (serum potassium of 2.0 mEq/liter)
was identified in one patient (no. 12) and one patient (no. 5)
had evidence of acute MI on postmortem examination.
Battery depletion or generator component failures were not
identified in any of the 22 devices that were analyzed after
death. Postshock tachyarrhythmia detection failure (patient
no. 5) and inappropriate device programming (patient no. 11)
theoretically might have played a role, because both can result
in a delay or complete withholding of needed antitachyarrhyth-
mia therapy. However, these potential device-related factors
could not be definitively implicated in the causation of SD in
any of the cases in our series (Fig. 2).
Discussion
In this multicenter experience with a third-generation ICD,
out-of-hospital SD was associated with VT or VF in nearly
two-thirds of cases. Death occurred despite successful, albeit
often protracted, device therapy. In over one-third of cases we
identified one or more clinical factors that might have contrib-
uted to SD, but none directly attributable to device failure.
Tachyarrhythmic versus nontachyarrhythmic SD. The
finding in the present third-generation ICD experience that
some two-thirds of SDs were associated with tachyarrhythmia
is consistent with observations from earlier devices in which at
least one-half of the cases of SDs occurred in association with
VT or VF events (2–4,7).
The proportion of out-of-hospital SDs deemed nontachya-
rrhythmic (28%) in the present series is quite similar to that
reported in patients without ICDs (14–16) and in patients with
first-generation (nonpacing) ICDs (5), even though the incor-
poration of antibradycardia pacing in current devices might be
expected to prevent, or at least reduce (17), the occurrence of
bradyarrhythmic SD reported to occur in patients with non-
pacing devices (18,19). This suggests that the mechanism(s)
involved in bradyarrhythmic SD is far more complex than in
cases of bradyarrhythmias due to conduction system disease,
which, in general, are readily amenable to pacing therapy.
Sudden death and device-related factors. In contrast to
earlier reports of SD in patients with first-generation ICDs
(3–5), device-related factors, such as battery-depleted or deac-
tivated ICDs and malfunctioning generators or defibrillation
leads, did not appear to play a role in the present third-
generation experience. However, relevant findings in two of
our study patients bear mention: potentially deleterious, inap-
propriate device programming and device malsensing. In one
patient (no. 11) unusual device programming (described ear-
lier) might have resulted in prolonged, untreated recurrent VT
that eventually led to VF, which, although ultimately termi-
nated after multiple shocks (Table 3), may have caused
irrevocable hemodynamic insult and death. The second patient
(no. 5) had evidence on the final stored intracardiac electro-
Figure 2. Final three stored tachya-
rrhythmic events (over a 38-min pe-
riod) in patient no. 5, showing (A)
sustained monomorphic VT termi-
nated by a 550-V shock (*) after
failed successive antitachycardia pac-
ing therapies (ATP), occurring at
17:06 h with patient abruptly collaps-
ing and, despite bystander cardiopul-
monary resuscitation, found 6 min
later by the emergency medical staff
to be pulseless; (B) polymorphic VT
successfully treated with a single
shock after failed ATP, occurring at
17:43 h after unsuccessful advanced
resuscitative efforts by the emergency
medical staff and subsequently the
emergency room staff; and (C) 1 min
later, ongoing polymorphic VT, after
ineffective ATP, inappropriately rede-
tected as sinus rhythm (SRD). Note
the progressive decrease and variabil-
ity in the amplitude of the electro-
grams preceding SRD.
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gram of inappropriate redetection of sinus rhythm in the
setting of ongoing polymorphic VT (Fig. 2C); however, this
event occurred '38 min after conversion of VT (without
restoration of pulse) by the ICD (Fig. 2A). Previously, failure
to redetect VF has been reported only in connection with
laboratory-induced arrhythmias (20–23).
Reduced effectiveness of antitachyarrhythmia therapy. Al-
though the ICD ultimately terminated most of the tachya-
rrhythmic episodes, the observed 64% first-shock (biphasic
waveform) success rate for the final (#11) fibrillation zone
tachyarrhythmic episodes was lower than the '93% value
reported for similar patients with comparable DFTs
(12,24,25), and even below that described with monophasic
shocks (26). In addition, we observed an overall antitachy-
cardia pacing success rate of only 60% compared with a
reported success rate of 92% to 97% in patients similar to
ours (12,24 –26).
Despite the statistical nature of defibrillation success (27), a
purely random basis for all the first-shock therapy failures in
this series is unlikely given the low implant DFTs, the high
proportion of patients known to have received appropriate and
successful ICD therapies (before death) and the one to three
normal premortem VF tests in our study group. Conceivably,
some first-shock failures might have been due to a subthresh-
old programmed energy, because in 43% of the patients the
programmed first defibrillation shock voltage was only margin-
ally greater, and in some cases equal to or lower than the
implant DFT, not in keeping with the recommended “safety
margin” (28). Under ordinary conditions, the DFT for an
epicardial system is expected to remain stable over time (29).
The increased frequency of first-shock failures in our series,
therefore, implicates dynamic factors that subacutely or
acutely altered adversely the energy requirement for terminat-
ing VT or VF, as suggested by premortem worsening CHF in
40% of our patients and preterminal symptoms suggestive of
ischemia in one-third of witnessed SDs.
Potential mechanisms of SD patients with ICDs. Although
the ultimate rhythm in patients dying suddenly with (or
without) an ICD is expected to be asystole or EMD, such an
outcome can arise directly as an initial, pacing-unresponsive
bradyarrhythmia, or indirectly as the sequel to one or more VT
or VF events. Acute EMD (without antecedent VT or VF) can
occur on a primary cardiac (e.g., acute MI) or noncardiac basis
(e.g., massive pulmonary embolism). Interpretation of VT or
VF in the SD setting is more complex. Clearly, an acute
pathophysiologic derangement, such as ischemia, can trigger
VT or VF; in some cases, however, even if VT or VF so
initiated is promptly detected and treated appropriately by the
ICD (“effective” therapy), asystole or EMD can follow (2–
5,18,19). Moreover, rapidly recurrent VT or VF events can,
despite successful treatment, lead to eventual mechanical
failure either from repeated bouts of myocardial hypoperfu-
sion or from potentially harmful effects of defibrillating shocks
on ventricular function in chronically failing myocardium
(30,31), as suggested by the markedly reduced baseline LVEF
(mean 0.25) in the present patient group compared with the
Table 3. Summary of Device Responses and Outcome for Stored Tachyarrhythmic Events Obtained From Postmortem Device Analysis*
Pt.
No.
Final Programmed ICD Variables Tachyarrhythmic Therapy Events
Tachy
Zone
Detection
Intervals
CL (ms)
Tiered Therapies† Difference (V)
Between First Fib
Shock and DFT
No. of
Detections
No. of Shocks
First Second Final Aborted Delivered‡
1 Tach 430 ATP 100 750 22
Fib 270 300 500 750 250 11 4 15
2 Tach 480 ATP 200 750 4
Fib 330 500 650 750 150 6 0 13
3 Tach 360 ATP 300 750 1
Fib 270 600 650 750 200 80 5 82
4 Tach 375 300 500 750 11
Fib 280 650 750 750 100 3 5 26
5 Tach 350 ATP 550 750 3
Fib 270 550 650 750 50 0 0 2
6 Fib 360 750 750 750 280 9 10 16
9 Tach 415 ATP 300 750 2
Fib 300 400 650 750 50 4 0 12
10 Fib 330 500 650 750 50 3 4 0
11 Tach 460 ATP OFF OFF 105
Fib 330 500 650 750 200 3 2 8
12 Fib 360 650 750 750 0 1 4 2
13 Tach 430 ATP 100 550 7 0 0
Fib 300 300 100 750 0 0 — —
14 Fib 350 650 700 750 250 1 0 1
15 Fib 330 750 750 750 200 4 7 5
16 Tach 400 ATP 150 600 3
Fib 300 400 550 750 100 23 11 94
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'0.30 to 0.35 range typical of patients in large ICD series
(12,13,26).
Submaximal first-shock energies for VF and, more im-
portantly, a lower than 100 V (;10 J) first-shock safety
margin, as programmed in 86% and 43%, respectively, of
our cases of tachyarrhythmia-associated SD (Table 3) may
be sufficient under relatively stable laboratory testing con-
ditions but may be inadequate during acute pathophysio-
logic changes.
Study limitations. The complexities of clarifying the
nature of “terminal” events associated with SD are well
known (32,33) and may not be clarified in the case of the
ICD recipient dying suddenly (7,33). Despite availability of
event markers and time-stamped stored electrograms, there
often remain uncertainties about the precise timing of the
fatal event. Moreover, autopsies were performed in only
three of our patients. A higher autopsy rate might have
provided additional insight into the mechanisms of SD in
our patient group; for instance, evidence for some acute
events would help to explain both the immediate cause of
death (in some cases noncardiac [7]) and the reduced
effectiveness of initial ICD therapies. In addition, the
present series involved epicardial lead systems only and
devices from a single manufacturer; however, there are no
reasons to suspect device-specific differences in the final
event(s), although with the current widespread use of
transvenous lead systems, ICD lead failures might play a
larger role in the cause of SD in the future (20 –23,34).
Conclusions. The present study suggests that, by and large,
SD in patients with ICD reflects acute myocardial mechanical
deterioration, with “incidental” tachyarrhythmias or brady-
arrhythmias that, though effectively treated by the device, may
still lead to death. However, whether or not the already
remarkably low SD rate in device-treated patients can be
further reduced ultimately would depend on the mechanism(s)
of SD in ICD recipients. The possibility that some cases of SD
in patients with ICDs might be preventable merits continued
investigation.
Table 3. Continued
Summary of ICD Therapy Outcome for Most Recent (#11) Tachyarrhythmic Episodes
Success of
First Therapy§
No. of Episodes\
Requiring $2
Successive Shocks
Maximal Successive No.
of Shocks¶ (and Time
[s]) to Redetect SR
Final Tachy Therapy#
Tachy Morphology
(CL [ms]) Successful
1/1 0 1 (,10)
8/11 2 3 (30–40) VF (,250) Yes
2/5 0
7/8 (1) 6 ($630–640) PVT (300) Yes
0/1 0
11/11 0 1 (10–20) VF (,250) Yes
4/11 4 3 (25–35)
1/4 2 (1) 5 (65–75) PVT (320) No
0/3 0
(2/2) 0 1 (30–40) PVT (300) Inappropriate SRD
7/9 2 6 ($630–640) PVT (260) Yes
0/2 0
3/5 (1) 6 ($630–640) PVT (280) Yes
NA NA NA PVT (240) Aborted Spontaneously
8/10
2/3 (1) 6 ($630–640) PVT (,250) Aborted spontaneously**
1/1 0 1 (5–15) VF (,250) Yes
7/7 0 1 (5–15) MVT (400) Yes
1/1 0 1 (,10) MVT (250) Yes
4/4 0 1 (15–25) VT (300) Aborted spontaneously**
1/11 7 3 (95–105) VF (,250) Aborted spontaneously**
*Excluding patient nos. 7 and 8, who did not have postmortem device interrogation. Patient numbers correspond to those listed in Table 1. †Numeric values
represent shock voltage for cardioversion (Tach zone) or defibrillation (Fib zone). ‡Shocks delivered for tachyarrhythmias in either Tach or Fib zone. §Denominator
refers to the number of first therapy attempts (#11) in either Tach or Fib zone. Value in parentheses reflects Fib therapy after failed ATP. \Number in parentheses
denotes episodes after failed ATP and/or low energy cardioversion. ¶For a given tachyarrhythmic episode; time refers to duration from delivery of the first therapy to
redetection of “sinus rhythm” for a given tachyarrhythmic episode (therapy duration); 630 to 640 s is the maximal time reported even if the actual duration is greater.
#For the most recent (final) tachyarrhythmic episode; successful outcome of delivered therapy is based on documented (from data log and stored electrogram)
termination of final tachyarrhythmic episode. **Penultimate (within seconds of final) stored electrogram showed appropriate and successful therapies. ATP 5
antitachycardia pacing; CL 5 cycle length; Fib 5 fibrillation; MVT 5 monomorphic ventricular tachycardia; PVT 5 polymorphic ventricular tachycardia; SRD 5 sinus
redetection; SR 5 sinus rhythm or any rhythm at a rate less than the programmed tachycardia detection rate; Tach 5 tachycardia; Tachy 5 tachyarrhythmia; other
abbreviations as in Table 1.
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Appendix
Participating Centers and Investigators
Allegheny General Hospital, Pittsburgh, Pennsylvania: Richard Fogo-
ros, MD; Cleveland Clinic Foundation, Cleveland, Ohio: Bruce Wilcoff,
MD; Cottage Hospital, Santa Barbara, California: Joseph Ilvento, MD;
Good Samaritan Hospital, Los Angeles, California: David Cannom,
MD; Holy Cross Hospital, Ft. Lauderdale, Florida: Richard Luceri, MD;
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania:
Francis Marchlinski, MD; Humana Hospital, Las Vegas, Nevada: David
Navratil, MD; Illinois Masonic Medical Center, Chicago, Illinois: Rich-
ard Kehoe, MD; Iowa Heart Center, Des Moines, Iowa: Steven Bailin,
MD; Massachusetts General Hospital, Boston, Massachusetts: Jeremy
Ruskin, MD; Methodist Hospital of Memphis, Memphis, Tennessee:
James Potterfield, MD; Sequoia Hospital, Redwood City, California:
Roger Winkle, MD; St. Joseph’s Hospital, Milwaukee, Wisconsin: Peter
Chapman, MD; St. Vincent Hospital, Indianapolis, Indiana: Lawrence
Gering, MD; University of Colorado, Denver, Colorado: Michael Reiter,
MD; University Hospital of Hannover, Hannover, Germany: Hans-
Joachim Trappe, MD; Virginia Mason Clinic, Seattle, Washington:
Christopher Fellows, MD; Western Pennsylvania Hospital, Pittsburgh,
Pennsylvania: Barry Alpert, MD.
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